Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 3.4.24.B4 extracted from

  • Reiter, L.A.; Freeman-Cook, K.D.; Jones, C.S.; Martinelli, G.J.; Antipas, A.S.; Berliner, M.A.; Datta, K.; Downs, J.T.; Eskra, J.D.; Forman, M.D.; Greer, E.M.; Guzman, R.; Hardink, J.R.; Janat, F.; Keene, N.F.; Laird, E.R.; Liras, J.L.; Lopresti-Morrow, L.L.; Mitchell, P.G.; Pandit, J.; Robertson, D.; Sperger, D.
    Potent, selective pyrimidinetrione-based inhibitors of MMP-13 (2006), Bioorg. Med. Chem. Lett., 16, 5822-5826.
    View publication on PubMed

Inhibitors

Inhibitors Comment Organism Structure
4-(4-[[5-(2-ethoxyethyl)-2,4,6-trioxohexahydropyrimidin-5-yl]oxy]phenoxy)-N-(2-fluorobenzyl)benzamide 50% inhibition at 01.1 nM, comparison with inhibition of matrix metalloproteinases MMP-2, MMP-8, MMP-12 Rattus norvegicus
4-(4-[[5-(2-ethoxyethyl)-2,4,6-trioxohexahydropyrimidin-5-yl]oxy]phenoxy)-N-(3-fluorobenzyl)benzamide 50% inhibition at 0.85 nM, comparison with inhibition of matrix metalloproteinases MMP-2, MMP-8, MMP-12 Rattus norvegicus
4-(4-[[5-(2-ethoxyethyl)-2,4,6-trioxohexahydropyrimidin-5-yl]oxy]phenoxy)-N-phenylbenzamide 50% inhibition at 0.84 nM, comparison with inhibition of matrix metalloproteinases MMP-2, MMP-8, MMP-12 Rattus norvegicus
4-(4-[[5-(2-ethoxyethyl)-2,4,6-trioxohexahydropyrimidin-5-yl]oxy]phenoxy)-N-pyridin-3-ylbenzamide 50% inhibition at 0.40 nM, comparison with inhibition of matrix metalloproteinases MMP-2, MMP-8, MMP-12 Rattus norvegicus

Organism

Organism UniProt Comment Textmining
Rattus norvegicus
-
rat fibrosis model
-